Search clinical trials for: Withdrawal of immunosuppression and donor lymphocyte infusion

Total 17968 results

University of California, San Francisco
Johns Hopkins All Children's Hospital

Completed

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia | Chronic Myelogenous Leukemia | Biphenotypic Leukemia | Pre-leukemic Syndromes | Monosomy 7 | Bone Marrow Clonal Malformations

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Beth Israel Deaconess Medical Center; Brigham...

Completed

Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant

Hematologic Malignancy

United States
Assistance Publique - Hôpitaux de Paris
Pierre and Marie Curie University; Paris 12 Val de Marne University

Completed

Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation (ILD-TK01)

Hematological Malignancy

France
St. Petersburg State Pavlov Medical University

Active, not recruiting

Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy

Hematologic Malignancy

Russian Federation
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Completed

MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT

Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte Infusion

China
Masonic Cancer Center, University of Minnesota

Completed

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

AML | MDS | Leukemia, Lymphocytic, Acute | Leukemia, Myeloid, Chronic

United States
Peking University People's Hospital

Unknown

Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant

Acute Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte Infusion | Graft-versus-host Disease

China
Hong Kong Children's Hospital

Recruiting

CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

Hematopoietic Organs; Disorder

Hong Kong
Institut Paoli-Calmettes

Not yet recruiting

Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML (ELIT-AML01)

Acute Myeloid Leukemia

France
Rigshospitalet, Denmark

Recruiting

Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial (IDEAL)

AML/MDS

Denmark
Washington University School of Medicine
National Cancer Institute (NCI); MacroGenics

Recruiting

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Relapsed Acute Myeloid Leukemia

United States
University Hospital Tuebingen

Recruiting

CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT (CD45RADLIHaplo)

Hematologic Malignancy

Germany
National University Hospital, Singapore
Singapore General Hospital

Unknown

T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Singapore
Assistance Publique - Hôpitaux de Paris
Pierre and Marie Curie University; Université Paris XII

Completed

Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion (ILD-Treg)

Hematologic Neoplasms | Relapse

France
National Cancer Institute (NCI)

Terminated

Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemias | Multiple Myeloma With Plasmacytoma

United States
Nelson Chao

Terminated

Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT

Cytomegalovirus Infections

United States
Suping ZHANG

Recruiting

Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

Acute B-cell Lymphoblastic Leukemia

China
Seoul National University Hospital

Terminated

Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2

Metastatic Malignant Melanoma and Renal Cell Carcinoma

Korea, Republic of
Mitchell Horwitz, MD

Completed

Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant

Hematological Malignancies

United States
Baptist Health South Florida

Active, not recruiting

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Myeloid Malignancy | Lymphoid Leukemia, Acute | Plasma Cell Tumor

United States
Istituto Clinico Humanitas

Completed

Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).

Infection | Graft Vs Host Disease | Hematological Malignancy | Bone Marrow Transplant Complications | Bone Marrow Transplant Infection

Italy
M.D. Anderson Cancer Center
Ziopharm Oncology

Completed

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

Lymphoma | Leukemia

United States
Sumithira Vasu

Completed

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Minimal Residual Disease

United States
Wake Forest University Health Sciences

Terminated

Donor Lymphocyte Infusion After Alternative Donor Transplantation

Immunodeficiency

United States
Haukeland University Hospital

Completed

Effects and Interactions of Liquorice and Grapefruit on Glucocorticoid Replacement Therapy in Addison's Disease

Addison Disease

Norway
Monica Thakar

Completed

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | CNS Tumors

United States
The First Affiliated Hospital of Soochow University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Acute Myeloid Leukemia

China
Abramson Cancer Center of the University of Pennsylvania

Completed

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Masonic Cancer Center, University of Minnesota
Incyte Corporation

Completed

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloid and Monocytic Leukemia

United States
GlaxoSmithKline

Completed

Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
University of California, San Francisco
Hellman Foundation

Completed

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

Juvenile Myelomonocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Acute Lymphoid Leukemia

United States
Kiadis Pharma

Terminated

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Lymphoma | Myeloid Leukemia | Myeloproliferative Disorders | Multiple Myeloma | Myelodysplastic Syndrome | Lymphoblastic Leukemia

Canada, Netherlands, Germany, Belgium, United States, Italy, United Kingdom
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Not yet recruiting

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

United States
Carlos Graux, MD, PhD
Celgene Corporation; Belgian Hematological Society

Completed

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Belgium
Groupe Francophone des Myelodysplasies
Astex Pharmaceuticals, Inc.

Active, not recruiting

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

AML | MDS

France
King's College Hospital NHS Trust
Leukemia Research Fund; Department of Health; Elimination of Leukaemia Fund

Unknown

Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 (RFUSIN2-AML1)

Leukemia, Myeloid, Acute

United Kingdom
Kiadis Pharma

Completed

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Hematologic Diseases | Hematologic Malignancies

Canada
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

AML | MDS

France
Antonio M Jimenez Jimenez
AbbVie

Not yet recruiting

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Terminated

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

Myeloma

United States
Andalusian Initiative for Advanced Therapies -...
Iniciativa Andaluza en Terapias Avanzadas

Withdrawn

Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies

Transplant-Related Hematologic Malignancy

Spain
Northwell Health
New York Blood Center

Completed

Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies

Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Post Transplant Donor Lymphocyte Infusion

Multiple Myeloma | AML | Myelodysplastic Syndrome | Leukemia, Lymphocytic, Acute | Lymphomas | Leukemia, Myeloid, Chronic | Leukemia, Lymphocytic, Chronic

United States
Stanford University
Northwestern University; California Institute for Regenerative Medicine (CIRM)

Recruiting

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

Living Donor Kidney Transplantation

United States
Ludwig-Maximilians - University of Munich
Amgen

Withdrawn

Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab (DLI-TARGET)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia in Remission | B-Cell Acute Lymphoblastic Leukemia | B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation

Germany
University of Wisconsin, Madison

Recruiting

BK With VST for Kidney Transplant Patients

BK Virus Infection | Kidney Transplant Infection

United States
National Institute of Allergy and Infectious Diseases...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Immune...

Completed

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients (iWITH)

Liver Transplantation | Immunosuppression | Liver Transplant Recipients

United States, Canada
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Completed

Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients (WISP-R)

Liver Transplantation | Liver Transplant

United States
Hospital Clinic of Barcelona
Fondo de Investigacion Sanitaria; European Commission; TcLand Expression S.A.

Unknown

Assessment Of the Safety and Benefit of Prospective Immunosuppressive Drug Withdrawal in Liver Transplantation and Prediction of Operational Tolerance

Liver Transplantation

Spain
Angus W. Thomson PhD DSc
University of Pittsburgh

Active, not recruiting

DCreg in Living Donor Liver Transplantation

Living Donor Liver Transplantation

United States

Search clinical trials for: Withdrawal of immunosuppression and donor lymphocyte infusion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations